Antibiotic Treatment for Bronchiectasis

Acute Exacerbations

The European Respiratory Society recommends treating acute exacerbations with 14 days of antibiotics selected based on prior sputum microbiology 1
For non-severe exacerbations, the first-line empirical oral antibiotic is Amoxicillin-clavulanate, which covers common pathogens including H. influenzae, S. pneumoniae, and M. catarrhalis 2
Ciprofloxacin is the best oral anti-pseudomonal agent and should be used empirically if risk factors for P. aeruginosa exist 2
Treatment duration should be 10-14 days for P. aeruginosa infections, longer than the standard 7-10 days for other pathogens 2
The European Respiratory Society recommends obtaining sputum cultures before starting antibiotics and adjusting empirical therapy once culture results are available 2

The European Respiratory Society recommends long-term antibiotics only for patients with ≥3 exacerbations per year, after optimizing airway clearance and treating underlying causes 3, 4, 5, 1
For chronic P. aeruginosa infection, inhaled colistin is the first-line prophylactic treatment, which significantly prolonged time to exacerbation in adherent patients 4, 5, 1
For non-Pseudomonas infections, oral macrolides are first-line prophylactic therapy, with azithromycin reducing exacerbations from 1.57 to 0.59 per patient over 6 months 6, 7
The dosing regimen for azithromycin is 250 mg three times weekly, which can be titrated based on response and adverse events 4

Before starting long-term macrolides, rule out active nontuberculous mycobacterial infection with at least one negative respiratory NTM culture 4, 5
Use caution in patients with significant hearing loss or balance issues when starting inhaled aminoglycosides 5
Monitor patients every 6 months for efficacy, toxicity, and continuing need, and monitor sputum culture and sensitivity regularly 4, 5, 1

Antimicrobial resistance is a significant concern, with macrolide resistance increasing 28% with erythromycin and reaching 88% after 12 months of azithromycin 3, 6, 7
Nebulized antibiotics, such as colistin and gentamicin, showed no antimicrobial resistance after 6-12 months 3, 6, 7
Avoid nebulized aztreonam due to increased adverse events and discontinuations compared to placebo, with no quality of life improvement 3, 7